Table 2. Association between characteristics of articles and statistically significant glycemic control and lipid level results that favor the test drug: Univariate exact logistic regression.

	Glycemic Control Results	Odds Ratio (95% CI)	P value	Lipid Level Results	Odds Ratio (95% CI)	P value
	that favor test drug (glitazone)			that favor test drug (glitazone)
	Favorable N/Total N (%)			Favorable N/Total N (%)
Journal Characteristics
Journal Impact factor
Range 0.34–44.02	40/56 (71)	1.010 (0.912, 1.130)	0.8902	23/56 (41)	0.924 (0.742, 1.138)	0.4789
Mean Value = 4.63
Std deviation = 6.06
Median Value = 2.84
Study characteristics
Comparison Groups
Placebo Controlled trial	27/28 (96)	1.00		11/25 ( 44)	1.00
Drug–drug Comparative trial	15/33 (46)	0.031 (0 , 0.245)	0	14/24 (58)	1.782 (0.499, 6.425)	0.4736
Sample size
Range 20–4360	42/61	1.002 (1.000, 1.005)	0.0394	25/49	0.999 (0.997, 1.001)	0.3720
Mean Value = 390
Std deviation = 590.4
Median Value = 252
Study design characteristics aimed at reducing bias
Randomization/Concealment of allocation
Adequate	11/15 (73)	1.331 (0.320, 6.669)	0.9292	5/10 (50)	0.950 (0.186, 4.868)	1.000
Blinding
Adequate	30/36 (83)	5.417 (1.459, 21.188)	0.0081	11/28 (39)	0.324 (0.083, 1.216)	0.1066
ITT Analysis
Adequate	36/48 (75)	4.200 (0.922, 19.750)	0.0664	18/38 (47)	0.514 (0.095, 2.464)	0.5453
Follow-up
Adequate	31/49 (63)	0.157 (0.003, 1.274)	0.1061	20/40 (50)	0.800 (0.138, 4.358)	1.0000
Appropriate Medication Dosing
Test drug – Adequate	42/60 (70)	Infinite (0.057, Infinite)	0.6230	25/48 (52)	Infinite (0.027, Infinite)	0.9796
Comparator drug - Adequate	14/30 (47)	1.750 (0.081, 110.507)	1.0000	12/21 (57)	0.667 (0.010, 14.997)	1.0000
Author characteristics
Corresponding Author Institutional Affiliation
Test drug company	16/16 (100)	Infinite (0.410, Infinite)	0.1176	8/13 (62)	Infinite (0.034, Infinite)	0.8571
Any other industry	0/1 (0)	–	–	0/1 (0)
Academic/Hospital	26/43 (61)	Infinite (0.037, Infinite)	0.8182	17/35 (49)	Infinite (0.023, Infinite)	1.0000
All Other	0/1 (0)	1.000		0/0 (0)
Funding information
Funding source
Test drug company/any other industry/other drug companies	0/2 (0)	0 (0, 1.656)	0.1111	2/2 (100)	Infinite (0.092, Infinite)	0.8667
Test drug company employee author/no formal disclosure	1/2 (50)	0.238 (0.003, 22.399)	0.7778	2/2 (100)	Infinite (0.092, Infinite)	0.8667
Any other drug company	2/6 (33)	0.119 (0.009, 1.190)	0.0769	0/5 (0)	0 (0, 0.886)	0.0373
No drug company	1/1 (100)	Infinite (0.006, Infinite)	1.0000	0/1 (0)	0 (0, 26.000)	0.8000
No funding disclosure	17/24 (71)	0.578 (0.122, 2.590)	0.6238	9/20 (45)	0.477 (0.109, 2.043)	0.4153
Test drug funding
Test drug funding	22/30 (73)	1.512 (0.445, 5.269)	0.6416	16/23 (70)	4.317 (1.126, 17.134)	0.0300
Corresponding Author Financial Ties
Test drug company ties/any other industry ties	2/5 (40)	0.133 (0.002, 3.502)	0.3939	2/3 (67)	2.000 (0.061, 156.747)	1.0000
Test drug company employee/no formal disclosure of ties	15/15 (100)	Infinite (0.064, Infinite)	0.5714	8/12 (67)	2.000 (0.173, 22.393)	0.8552
Any other industry ties	2/2 (100)	Infinite (0.009, Infinite)	1.0000	1/2 (50)	1.000 (0.010, 104.374)	1.0000
No disclosure of ties	18/32 (56)	0.257 (0.005, 2.776)	0.4388	10/25 (40)	0.667 (0.074, 6.103)	0.9987
Corresponding Author Test Drug Financial Ties
Test drug financial ties	22/26 (85)	4.125 (1.048, 19.525)	0.0409	13/21 (62)	2.167 (0.592, 8.099)	0.3025
First Author Financial Ties
Test drug company ties/any other industry ties	2/5 (40)	0 (0, 2.027)	0.1667	2/3 (67)	1.333 (0.036, 117.498)	1.0000
Test drug company employee/no formal disclosure of ties	5/5 (100)	1.00		3/5 (60)	1.000 (0.042, 23.663)	1.0000
Any other industry ties	2/2 (100)	1.00		1/2 (50)	0.667 (0.006, 78.249)	1.0000
No disclosure of ties	28/44 (64)	0 (0, 2.188)	0.2489	16/34 (47)	0.593 (0.045, 5.955)	0.9492
First Author Test Drug Financial Ties
Test drug financial ties	12/15 (80)	2.133 ((0.469, 13.331)	0.4588	8/13 (62)	1.788 (0.414, 8.297)	0.5762